Expand your proteome coverage
LC-MS delivers unbiased protein detection, including proteoforms. PEA offers exceptional sensitivity with high throughput and simplicity. Together, they offer the best of both worlds, expanding proteome insights and accelerating biomarker discovery and validation.
Complementary strengths of PEA and LC-MS
While PEA offers high performance in plasma with high-throughput, easy quantification, and streamlined workflows, Mass Spec enables unbiased detection of proteoforms, metabolites, and more, making them powerful, complementary tools in proteomics.
Dynamic Range
Without additional sample preparation, high-abundance proteins in plasma can mask low-abundance targets in LC-MS analysis. PEA enables low pg/mL-level detection without the need for depletion or fractionation, revealing immune biomarkers across a wide range of diseases.
Why combine LC-MS and PEA?
Researchers share their perspectives on why they combine both technologies
The combination of both technologies extends overall proteome coverage—leveraging LC-MS for unbiased proteoform analysis and PEA for high-throughput detection of low-abundance proteins.
Hear directly from respected scientists — Stephanie Hauck, Gabi Kastenmüller, Hanno Steen, Ann-Christine König, and Jochen Schwenk — as they share their perspectives on adopting this synergistic approach in the podcast and roundtable below.
Complementarity of mass spectrometry and PEA
Stephanie Hauck and Gabi Kastenmüller (Helmholtz Center Munich) discuss the emerging new era of proteomics, the great potential of studying the plasma proteome and the challenges involved.
The opportunities and challenges of combining technologies
Hanno Steen (Boston Children’s Hospital & Harvard Medical School), Ann-Christine König (Helmholtz Center Munich), and Jochen Schwenk (KTH Royal Institute of Technology) discuss the opportunities and challenges of combining affinity-based proteomics with LC-MS.
Integrating Mass Spectrometry and Affinity-Based Proteomics
Explore key takeaways from our recent expert roundtable on how mass spectrometry and affinity-based methods can work together.
What is possible when combining LC-MS and PEA?
Integrating LC-MS and PEA accelerates biomarker discovery and validation
A growing body of high-impact research highlights the value of combining LC-MS and PEA.
Researchers are using the two technologies in parallel to maximize actionable proteomic insights—or at different stages of the biomarker development pipeline, from discovery to validation of protein signatures. Explore the success stories in the resources below.
Discovery and validation of biomarker signatures
Dr. Hannah Schiff (University of Southampton) shares how she is using LC-MS to identify high-performance diagnostic signatures for tuberculosis (TB), and PEA panels to validate them.
Detailed technical comparison and examples of published research
This white paper explores how PEA™ and LC-MS differ and how they can work together. It includes examples from published research where the combined approach powered impactful discoveries.
